Ballicules.com
REMS restricted

Macitentan

OPSUMIT

Pronunciation: ma-si-TEN-tan (OP-sum-it)

Macitentan ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Macitentan ballicule

What it isEndothelin receptor antagonist; pulmonary arterial hypertension.

Why this oneCompared with bosentan, it penetrates tissue better and does not require routine monthly liver testing.

What limits itEmbryo-fetal toxicity requires restricted dispensing and pregnancy prevention. Anemia and peripheral edema can limit use.

Macitentan molecular structure (skeletal formula)
Molecular structure: Macitentan

FDA-approved for

FDA label

BOXED WARNING Embryo-fetal toxicity — contraindicated in pregnancy; exclude pregnancy before starting and use effective contraception during and for 1 month after treatment.
FDA dosingPopulationStartTargetMax
Pulmonary arterial hypertension (PAH)Adults10 mg QD10 mg QD10 mg QD

Renal Undefined

Hepatic Undefined

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy Contraindicated; teratogenic in animals at all doses; may cause fetal harm.

Lactation Advise not to breastfeed; no human data.

Cost

Macitentan (OPSUMIT)
Strength#/mogeneric $/moCostPlus
10 mgtab30 qdoffered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Macitentan is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Generic entry2021

⚠ BOXED WARNING

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk4 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Open Macitentan in the interactive console ↗